Prosecution Insights
Last updated: May 29, 2026

Examiner: PAGUIO FRISING, MICHELLE F

Tech Center 1600 • Art Units: 1626 1651

This examiner grants 70% of resolved cases

Performance Statistics

70.5%
Allow Rate
+10.5% vs TC avg
591
Total Applications
+40.7%
Interview Lift
941
Avg Prosecution Days
Based on 566 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
2.8%
§102 Novelty
52.5%
§103 Obviousness
4.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18332893 DOSING REGIMEN Non-Final OA Halozyme, Inc.
18628290 Bile Acids and Use in Disease Treatment Final Rejection The Regents of the University of California
18006382 DEGRADABLE HOLLOW SHELL PARTICLES FOR HIGH-THROUGHPUT SCREENING AND SORTING OF CELLS Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18024477 PROBIOTIC TREATMENTS FOR PARKINSON'S DISEASE Final Rejection California Institute of Technology
18311875 PHOTOBIOCONVERSION OF ELECTROCATALYSIS-DERIVED FORMATE Non-Final OA Alliance for Sustainable Energy, LLC
18371602 Fremyella diplosiphon as a Nutritional Feed Supplement for Aquaculture Non-Final OA Morgan State University
17754071 COMPOSITIONS AND METHODS USING ADENOSYLCOBALAMIN Final Rejection SOCIETE DES PRODUITS NESTLE S.A.
18601318 THERAPEUTIC AGENT FOR DISC HERNIATION Non-Final OA Seikagaku Corporation
17252446 SUBTILASE VARIANTS AND COMPOSITIONS COMPRISING SAME Final Rejection NOVOZYMES A/S
18413541 METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS Non-Final OA RESEARCH DEVELOPMENT FOUNDATION
18392662 TREATMENT OF ACUTE HEART FAILURE USING NITROUS OXIDE AND CHRONIC HEART FAILURE USING BOTULINUM TOXIN Non-Final OA Penland Foundation
18283114 ANTHOCYANIN BIOPRODUCTION IN A CELL-FREE MANUFACTURING SYSTEM Non-Final OA DEBUT BIOTECHNOLOGY, INC.
18268477 IMPROVED RECEPTOR-BINDING DOMAIN OF BOTULINUM NEUROTOXIN A AND USES THEREOF Non-Final OA Children's Medical Center Corporation
18258931 METHODS AND COMPOSITIONS Non-Final OA PLANT BIOSCIENCE LIMITED
17923296 COMPOSITIONS COMPRISING ENZYMES AND PROBIOTICS, AND METHODS FOR PREVENTING OR TREATING MACULAR DEGENERATION Final Rejection GenoFocus, Inc.
17947861 METHODS FOR DISEASE ASSESSMENT USING DRAIN FLUID Final Rejection THE WASHINGTON UNIVERSITY

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month